한글목차

임상시험용 AI 시장 규모는 2024년 13억 5,000만 달러로 평가되었고, 2030년에는 27억 4,000만 달러에 이를 것으로 예측되며, 2024년부터 2030년까지 CAGR은 12.4%가 될 것으로 전망됩니다.

효율성 향상, 단기간의 환자 모집, 데이터의 정확한 분석에 대한 수요 증가가 임상시험용 AI 시장을 뒷받침하고 있습니다. AI를 활용한 솔루션은 임상시험의 다양한 단계의 기간 단축을 지원하며, 예측 모델링과 인게이지먼트 전략을 통해 환자의 유지 수준을 향상시킵니다. 더불어 웨어러블이나 EMR 시스템의 이용 증가로 코스의 모든 단계에서의 모니터링이 용이해지기 때문에 임상시험용 AI 용도가 강화됩니다. 하지만 규제 규범, 터무니없이 높은 도입 비용, 데이터 유출 우려 등 몇 가지 장애물이 임상시험용 AI의 본격적인 이용을 가로막는 제약으로 작용하고 있습니다.

AI 기술을 응용하여 임상시험을 실시하는 분야에서는 모든 적응증 중 감염증이 가장 급속한 성장을 이룰 가능성이 높다고 보여지고 있습니다. 팬데믹(세계적 대유행)과 같은 질병의 유행에 대해 보다 신속하고 뛰어난 해결책을 요구하는 세계의 요청에 의해 이러한 개발은 매우 급속히 진행되고 있습니다. AI는 환자 등록 프로세스를 신속화하고 예측을 강화하며 임상 시험을 보다 적절하게 구성합니다. 감염병 대책 캠페인의 증가로 선진 기술, 특히 AI의 이용이 크게 증가하고 있습니다.

최종 사용자별로는 임상시험용 AI 시장은 제약 및 바이오파마기업, 연구기관 및 연구소, 의료 제공자, CRO, 의료기기 제조업체로 이분됩니다. 시장 점유율의 대부분은 제약 및 바이오파마 기업이 차지합니다. 이는 연구개발비가 매우 크기 때문이며, 그 결과 보다 신속한 의약품 개발 프로세스, 보다 우수한 임상시험 디자인, 환자 모집 강화를 위한 AI 적용이 기업에 있어 높아집니다. 이러한 AI 시스템은 대규모 데이터 세트의 복잡한 분석을 지원하고 시장으로의 제품 도입을 신속화하며 제약 분야의 경쟁에서 이기기 위해 매우 필수적인 증가하는 비용을 제어하기 위해 이러한 기업을 위해 설계되었습니다.

본 보고서에서는 세계의 임상시험용 AI 시장을 조사했으며, 제공 제품별, 기능별, 단계별, 전개모드별, 적응증별, 기술별, 용도별, 최종 사용자별, 지역별 동향 및 시장에 진입 하는 기업의 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 서문
• 시장 역학
• 시장 역학
• 업계 동향
• 생태계 분석
• 사례 연구 분석
• 밸류체인 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구매 기준
• 규제 상황
• 특허 분석
• 기술 분석
• 가격 분석
• 주된 회의 및 이벤트(2024-2025년)
• 고객의 비즈니스에 영향을 미치는 동향 및 혼란
• 언멧 요구 및 최종 사용자의 기대
• 투자 및 자금조달 시나리오
• 임상시험용 AI 시장에 대한 AI 및 생성형 AI의 영향

제6장 임상시험용 AI 시장 : 제공 제품별

• 서문
• 엔드 투 엔드 솔루션
• 틈새 솔루션
• 기술 공급자
• 서비스

제7장 임상시험용 AI 시장 : 기능별

• 서문
• 피험자 모집
• 시험 설계 최적화
• 데이터 관리 및 품질 관리
• 부작용 예측 및 검출
• 약물 재사용
• 규제 준수

제8장 임상시험용 AI 시장 : 페이즈별

• 서문
• 페이즈 I 임상시험
• 페이즈 II 임상시험
• 페이즈 III 임상시험
• 페이즈 IV 임상시험

제9장 임상시험용 AI 시장 : 전개 모드별

• 서문
• 클라우드 기반 솔루션
• 온프레미스 솔루션

제10장 임상시험용 AI 시장 : 적응증별

• 서문
• 종양학
• 신경질환
• 심장혈관 질환
• 대사성 질환
• 감염증
• 면역 질환
• 기타

제11장 임상시험용 AI 시장 : 기술별

• 서문
• 머신러닝
• 자연언어처리
• 컴퓨터 비전
• 로봇식 프로세스 자동화
• 기타

제12장 임상시험용 AI 시장 : 용도별

• 서문
• 바이오마커
• 세포 및 유전자 치료
• 재생 의료
• 의료기기 및 진단

제13장 임상시험용 AI 시장 : 최종 사용자별

• 서문
• 제약 및 바이오 의약품 기업
• 연구기관 및 연구소
• 의료 제공자
• CRO
• 의료기기 제조업체

제14장 임상시험용 AI 시장 : 지역별

• 서문
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 일본
  • 중국
  • 인도
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타

제15장 경쟁 구도

• 서문
• 주요 진입기업의 전략 및 강점
• 수익 분석(2019-2023년)
• 시장 점유율 분석(2023년)
• 기업평가 매트릭스 : 주요 진입기업(2023년)
• 기업평가상한 : 스타트업 및 중소기업(2023년)
• 기업평가 및 재무지표
• 브랜드 및 제품 비교
• 경쟁 시나리오

제16장 기업 프로파일

• 주요 진출기업
  • IQVIA INC.
  • DASSAULT SYSTEMES(MEDIDATA)
  • INSILICO MEDICINE
  • TEMPUS AI, INC.
  • NVIDIA CORPORATION
  • SAAMA
  • PHESI
  • PATHAI, INC.
  • UNLEARN.AI, INC.
  • DEEP6.AI
  • MICROSOFT
  • IBM
  • CONCERTAI
  • AICURE
  • MEDIAN TECHNOLOGIES
  • LANTERN PHARMA INC.
  • CITELINE, A NORSTELLA COMPANY
  • TRINETX, LLC
• 기타 기업
  • REVIVEMED INC.
  • EURETOS
  • VERISIM LIFE
  • TRIOMICS
  • ARDIGEN
  • QUANTHEALTH LTD.
  • DEEP GENOMICS

제17장 부록

영문목차

The AI in clinical trials market is projected to reach USD 2.74 billion by 2030 from USD 1.35 billion in 2024, at a CAGR of 12.4% from 2024 to 2030. The growing demand for improvements in effectiveness, recruitment of patients in a shorter duration, and accurate analysis of data is the key factor fuelling the market for AI in clinical trials. Solutions powered by AI assist in shortening the duration of various phases of the trial and also in improving patient retention levels using predictive modelling and engagement strategies. In addition, the increase in use of wearables and EMR systems facilitates monitoring at every stage of the course, hence reinforcing the application of AI in trials. Nevertheless, a few obstacles including regulatory norms, prohibitively high cost of implementation and fears of data breach act as constraints hindering the full-scale use of AI in clinical trials.

"Infectious diseases had the fastest growth rate in the AI in clinical trials market during the forecast period, by indication."

In the sector of conducting clinical studies with the application of AI technologies, it is likely that among all indications infectious diseases will experience the most rapid growth. Such development is very fast owing to the global appeal for quicker and better solutions against disease outbreaks such as the pandemic. AI speed up the patient enrolment process, enhance forecasting, better structure the trials all of which help to deal with fast spreading viruses in a common sense. There has been a significant rise in the use of advanced technologies especially AI owing to the increased campaigns of fighting infectious diseases.

"By end user, the pharmaceutical & biopharma companies to account for largest market share in 2023."

By end user, AI in clinical trials market is bifurcated into pharmaceutical & biopharma companies, research institutes & labs, healthcare providers, contract research organizations, and medical device manufacturers. The majority of the market share to be occupied by pharmaceutical & biopharma companies' segment. This is due to the great extent of research and development expenditure, which in turn raises the application of AI for faster drug development processes, better clinical trial designs as well as enhanced patient recruitment for the companies. Such AI systems are designed for such firms to help in a complex analysis of large data sets, quicken the introduction of products into the market, and control the ever-increasing costs which are very essential in winning the competition in the case of the pharmaceutical sector.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in clinical trials market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific AI in clinical trials market is projected to register highest CAGR during the forecast period. The Asia Pacific is benefiting from the fast-developing healthcare infrastructure, advances in AI technologies and expansion of clinical research. With countries such as China, India and Japan encouraging the use of AI in healthcare to facilitate large and varied populations and organize clinical trials more efficiently. Furthermore, owing to the favourable government policies, increasing proliferations of contract research organizations (CROs) and cheaper operation costs in the market relative to the Western regions, many multinational pharmaceutical companies are making it their business to invest in AI clinical trials within the region.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: Managers (40%), Directors (35%), and Others (25%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• Saama. (US)
• Dassault Systemes (Medidata) (France)
• Phesi (US)
• PathAI, Inc. (US)
• Unlearn.ai, Inc. (US)
• Deep6.ai (US)
• Microsoft (US)
• IBM (US)
• NVIDIA Corporation (US)
• Insilico Medicine (US)
• ConcertAI. (US)
• AiCure. (US)
• Median Technologies. (France)
• Lantern Pharma Inc. (US)
• Citeline, a Norstella Company (US)
• Tempus AI, Inc. (US)
• TriNetX, LLC (US)
• ReviveMed Inc. (US)
• Euretos. (US)
• VeriSIM Life. (US)
• Triomics (US)
• Ardigen (Poland)
• QuantHealth Ltd. US)
• DEEP GENOMICS. (Canada)

Research Coverage:

This research report categorizes the AI in clinical trials market by offerings (end-to-end solutions, niche solutions, technology providers and services), function (patient recruitment, trial design optimization, data management & quality control, adverse event prediction & detection, drug repurposing, and regulatory compliance), phase (phase I, phase II, phase III and phase IV), deployment mode (cloud-based solutions, and on-premise solutions), indication (oncology, neurological diseases, cardiovascular diseases, metabolic diseases, infectious diseases, immunology diseases, and others (gastrointestinal, respiratory & reproductive), technology (machine learning, NLP, computer vision, robotic process automation, and others), application (biomarkers, cell & gene therapy, regenerative medicine, and medical devices & diagnostics), end user (pharmaceutical & biotechnology companies, research institutes & labs, healthcare providers, contract research organizations (CROs), and medical device manufacturers) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in clinical trials market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in clinical trials market. Competitive analysis of upcoming startups in the AI in clinical trials market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in clinical trials market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers: (Growing demand for faster and more efficient drug development), restraints (High costs associated with implementing AI solutions), opportunities (Increased focus on precision medicine), and challenges (Complexity of integrating AI into traditional clinical trial frameworks) influencing the growth of the AI in clinical trials market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in clinical trials market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the AI in clinical trials market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in clinical trials market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as IQVIA Inc. (US), Dassault Systemes (Medidata) (France), Tempus AI, Inc. (US), Insilico Medicine (US), ConcertAI. (US), AiCure. (US) PathAI, Inc. (US), etc. among others in AI in clinical trials market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources for secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key sources for primary data
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE REVENUE SHARE ANALYSIS
  • 2.2.2 PARENT MARKET APPROACH
  • 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 MARKET SEGMENT ASSESSMENT
  • 2.2.5 GEOGRAPHIC MARKET ASSESSMENT
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN CLINICAL TRIALS MARKET OVERVIEW
• 4.2 AI IN CLINICAL TRIALS MARKET, BY REGION
• 4.3 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER AND COUNTRY
• 4.4 AI IN CLINICAL TRIALS MARKET: GEOGRAPHICAL SNAPSHOT
• 4.5 AI IN CLINICAL TRIALS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
• 5.3 MARKET DYNAMICS
  • 5.3.1 DRIVERS
    • 5.3.1.1 Increasing demand for personalized treatments
    • 5.3.1.2 Support for decentralized and global trials
    • 5.3.1.3 Regulatory compliance and ethical considerations
    • 5.3.1.4 Automated document review for better regulatory compliance
    • 5.3.1.5 Focus on real-time data management and analysis
  • 5.3.2 RESTRAINTS
    • 5.3.2.1 Data privacy and security concerns
    • 5.3.2.2 Integration challenges with legacy systems and resistance from healthcare professionals
    • 5.3.2.3 High implementation cost and need for skilled AI professionals
  • 5.3.3 OPPORTUNITIES
    • 5.3.3.1 Use of predictive analytics in clinical trials
    • 5.3.3.2 Development of virtual control arms for faster trials
    • 5.3.3.3 Integrating natural language processing into clinical trials for data extraction
  • 5.3.4 CHALLENGES
    • 5.3.4.1 Addressing algorithm bias and fairness
    • 5.3.4.2 Insufficient technical expertise in AI-based solutions
• 5.4 INDUSTRY TRENDS
  • 5.4.1 INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS
  • 5.4.2 RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 CASE STUDY ANALYSIS
  • 5.6.1 AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
  • 5.6.2 REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
  • 5.6.3 BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 BARGAINING POWER OF SUPPLIERS
  • 5.8.2 BARGAINING POWER OF BUYERS
  • 5.8.3 THREAT OF SUBSTITUTES
  • 5.8.4 THREAT OF NEW ENTRANTS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.9.2 KEY BUYING CRITERIA
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS
  • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Machine learning
    • 5.12.1.2 Natural language processing
    • 5.12.1.3 Computer vision
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 Internet of things
    • 5.12.2.2 Cloud computing
  • 5.12.3 ADJACENT TECHNOLOGIES
    • 5.12.3.1 Advanced genomics
• 5.13 PRICING ANALYSIS
  • 5.13.1 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
  • 5.13.2 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022-2024
• 5.14 KEY CONFERENCES & EVENTS, 2024-2025
• 5.15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.16 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.16.1 UNMET NEEDS
  • 5.16.2 END-USER EXPECTATIONS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.2.1 Case study
    • 5.18.2.2 Clinical trials market
    • 5.18.2.3 eClinical solutions market
    • 5.18.2.4 AI in biotechnology market
  • 5.18.3 USERS READINESS AND IMPACT ASSESSMENT
    • 5.18.3.1 User readiness
      • 5.18.3.1.1 Pharmaceutical & biopharmaceutical companies
      • 5.18.3.1.2 Contract research organizations
    • 5.18.3.2 Impact assessment
      • 5.18.3.2.1 User A: Healthcare providers
      • 5.18.3.2.2 User B: Research institutes & laboratories

6 AI IN CLINICAL TRIALS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS
• 6.3 NICHE SOLUTIONS
  • 6.3.1 HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH
• 6.4 TECHNOLOGY PROVIDERS
  • 6.4.1 NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
• 6.5 SERVICES
  • 6.5.1 CONSULTING SERVICES
    • 6.5.1.1 Consulting services to optimize trial design, enhance patient recruitment, and improve data management
  • 6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
    • 6.5.2.1 Need for smooth integration and optimization of AI technologies to boost segment growth
  • 6.5.3 TRAINING & EDUCATION SERVICES
    • 6.5.3.1 Need for skilled talent for managing complex AI systems to augment segment growth
  • 6.5.4 POST-SALES & MAINTENANCE SERVICES
    • 6.5.4.1 Development of complex AI systems and need for continuous improvement in AI algorithms to drive segment growth

7 AI IN CLINICAL TRIALS MARKET, BY FUNCTION

• 7.1 INTRODUCTION
• 7.2 PATIENT RECRUITMENT
  • 7.2.1 PATIENT IDENTIFICATION & SCREENING
    • 7.2.1.1 Reduced patient screening time and better accuracy than human clinicians to drive market
  • 7.2.2 PATIENT ENGAGEMENT & RETENTION
    • 7.2.2.1 Better personalized communication and support for clinical trials to propel market growth
  • 7.2.3 SITE OPTIMIZATION
    • 7.2.3.1 Cost-effective and improved participant recruitment and retention to fuel segment growth
• 7.3 TRIAL DESIGN OPTIMIZATION
  • 7.3.1 WORKFLOW MANAGEMENT
    • 7.3.1.1 Effective real-time tracking, automated reporting, and milestone monitoring to spur segment growth
  • 7.3.2 PREDICTIVE MODELING
    • 7.3.2.1 Ability to optimize trial design, predict risks, and identify effective treatment protocols to drive segment
  • 7.3.3 RISK MANAGEMENT
    • 7.3.3.1 AI-driven solutions for risk prediction to improve patient safety and data integrity
• 7.4 DATA MANAGEMENT & QUALITY CONTROL
  • 7.4.1 FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION
• 7.5 ADVERSE EVENT PREDICTION & DETECTION
  • 7.5.1 MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH
• 7.6 DRUG REPURPOSING
  • 7.6.1 DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES
• 7.7 REGULATORY COMPLIANCE
  • 7.7.1 COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH

8 AI IN CLINICAL TRIALS MARKET, BY PHASE

• 8.1 INTRODUCTION
• 8.2 PHASE I CLINICAL TRIALS
  • 8.2.1 FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI
• 8.3 PHASE II CLINICAL TRIALS
  • 8.3.1 NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI
• 8.4 PHASE III CLINICAL TRIALS
  • 8.4.1 NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH
• 8.5 PHASE IV CLINICAL TRIALS
  • 8.5.1 AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS

9 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE

• 9.1 INTRODUCTION
• 9.2 CLOUD-BASED SOLUTIONS
  • 9.2.1 PUBLIC CLOUD-BASED SOLUTIONS
    • 9.2.1.1 Reduced need for costly on-premises infrastructure and better regulatory compliance to fuel adoption
  • 9.2.2 PRIVATE CLOUD-BASED SOLUTIONS
    • 9.2.2.1 Better security and personalization for sensitive data to propel segment growth
  • 9.2.3 MULTI CLOUD-BASED SOLUTIONS
    • 9.2.3.1 Use of advanced predictive modeling for patient recruitment and site performance optimization to drive market
  • 9.2.4 HYBRID CLOUD-BASED SOLUTIONS
    • 9.2.4.1 Better flexibility in data management to reduce resource requirements in clinical trials
• 9.3 ON-PREMISES SOLUTIONS
  • 9.3.1 ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS

10 AI IN CLINICAL TRIALS MARKET, BY INDICATION

• 10.1 INTRODUCTION
• 10.2 ONCOLOGY
  • 10.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH
• 10.3 NEUROLOGICAL DISEASES
  • 10.3.1 COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON'S DISEASE TO SPUR MARKET GROWTH
• 10.4 CARDIOVASCULAR DISEASES
  • 10.4.1 RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT
• 10.5 METABOLIC DISEASES
  • 10.5.1 RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH
• 10.6 INFECTIOUS DISEASES
  • 10.6.1 RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES
• 10.7 IMMUNOLOGY DISEASES
  • 10.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
• 10.8 OTHER DISEASES

11 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY

• 11.1 INTRODUCTION
• 11.2 MACHINE LEARNING
  • 11.2.1 DEEP LEARNING
    • 11.2.1.1 Reduced chance of errors in clinical trials and enhanced data consistency to augment segment growth
  • 11.2.2 SUPERVISED LEARNING
    • 11.2.2.1 Supervised learning to focus on effective patient stratification, disease progression prediction, and biomarker identification
  • 11.2.3 UNSUPERVISED LEARNING
    • 11.2.3.1 Effective handling of complex and unstructured datasets to aid adoption in trial design and execution
  • 11.2.4 REINFORCEMENT LEARNING
    • 11.2.4.1 Dynamic learning capabilities to aid adoption in personalized medicine and precision oncology
  • 11.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
• 11.3 NATURAL LANGUAGE PROCESSING
  • 11.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT
• 11.4 COMPUTER VISION
  • 11.4.1 RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET
• 11.5 ROBOTIC PROCESS AUTOMATION
  • 11.5.1 ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY BY AUTOMATING ADMINISTRATIVE WORKFLOWS
• 11.6 OTHER TECHNOLOGIES

12 AI IN CLINICAL TRIALS MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 BIOMARKERS
  • 12.2.1 INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS
• 12.3 CELL & GENE THERAPY
  • 12.3.1 HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH
• 12.4 REGENERATIVE MEDICINES
  • 12.4.1 INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH
• 12.5 MEDICAL DEVICES & DIAGNOSTICS
  • 12.5.1 NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH

13 AI IN CLINICAL TRIALS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 13.2.1 HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH
• 13.3 RESEARCH INSTITUTES & LABORATORIES
  • 13.3.1 INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
• 13.4 HEALTHCARE PROVIDERS
  • 13.4.1 ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET
• 13.5 CONTRACT RESEARCH ORGANIZATIONS
  • 13.5.1 RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH
• 13.6 MEDICAL DEVICE MANUFACTURERS
  • 13.6.1 DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH

14 AI IN CLINICAL TRIALS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 14.2.2 US
    • 14.2.2.1 US to dominate North American AI in clinical trials market during study period
  • 14.2.3 CANADA
    • 14.2.3.1 Rising need for data standardization and increasing health expenditure to support market growth
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 14.3.2 UK
    • 14.3.2.1 High R&D investment by government organizations to augment market growth
  • 14.3.3 GERMANY
    • 14.3.3.1 Increased focus on research activities and strategic developments by pharma & biotech companies to drive market
  • 14.3.4 FRANCE
    • 14.3.4.1 Strong government support and focus on domestic drug research to propel market growth
  • 14.3.5 ITALY
    • 14.3.5.1 Increased R&D investments from pharmaceutical companies and reduced time for drug approvals to fuel market growth
  • 14.3.6 SPAIN
    • 14.3.6.1 Increased technological investments by private organizations and integrated healthcare systems to spur market growth
  • 14.3.7 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 14.4.2 JAPAN
    • 14.4.2.1 Well-established clinical trial infrastructure and advanced biomedical research to support market growth
  • 14.4.3 CHINA
    • 14.4.3.1 Low cost of clinical trials and availability of treatment-naive population to propel market growth
  • 14.4.4 INDIA
    • 14.4.4.1 Favorable government policies and high R&D expenditure by Indian pharmaceutical companies to spur market growth
  • 14.4.5 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 14.5.2 BRAZIL
    • 14.5.2.1 Increasing governmental support for innovation and growing biotechnology sector to drive market
  • 14.5.3 MEXICO
    • 14.5.3.1 Strong technological and research capabilities in AI applications to fuel market growth
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 14.6.2 GCC COUNTRIES
    • 14.6.2.1 Technological innovations and focus on precision medicines to augment market growth
  • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
• 15.3 REVENUE ANALYSIS, 2019-2023
• 15.4 MARKET SHARE ANALYSIS, 2023
  • 15.4.1 RANKING OF KEY MARKET PLAYERS
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Offering footprint
    • 15.5.5.4 Function footprint
    • 15.5.5.5 End-user footprint
• 15.6 COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 15.7 COMPANY EVALUATION & FINANCIAL METRICS
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 IQVIA INC.
    • 16.1.1.1 Products/Services/Solutions offered
    • 16.1.1.2 Recent developments
      • 16.1.1.2.1 Solution launches
      • 16.1.1.2.2 Deals
    • 16.1.1.3 MnM view
      • 16.1.1.3.1 Right to win
      • 16.1.1.3.2 Strategic choices
      • 16.1.1.3.3 Weaknesses & competitive threats
  • 16.1.2 DASSAULT SYSTEMES (MEDIDATA)
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products/Services/Solutions offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Solution launches
      • 16.1.2.3.2 Deals
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 INSILICO MEDICINE
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products/Services/Solutions offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Other developments
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 TEMPUS AI, INC.
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products/Services/Solutions offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Solution launches
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 NVIDIA CORPORATION
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products/Services/Solutions offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product and service launches
      • 16.1.5.3.2 Deals
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 SAAMA
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products/Services/Solutions offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Solution launches
      • 16.1.6.3.2 Deals
  • 16.1.7 PHESI
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products/Services/Solutions offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Solution launches
      • 16.1.7.3.2 Deals
  • 16.1.8 PATHAI, INC.
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products/Services/Solutions offered
  • 16.1.9 UNLEARN.AI, INC.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products/Services/Solutions offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Solution launches
      • 16.1.9.3.2 Deals
      • 16.1.9.3.3 Other developments
  • 16.1.10 DEEP6.AI
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products/Services/Solutions offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Solution launch
      • 16.1.10.3.2 Deals
  • 16.1.11 MICROSOFT
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products/Services/Solutions offered
    • 16.1.11.3 Recent developments
  • 16.1.12 IBM
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products/Services/Solutions offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
  • 16.1.13 CONCERTAI
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products/Services/Solutions offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Solution launches
      • 16.1.13.3.2 Deals
      • 16.1.13.3.3 Other developments
  • 16.1.14 AICURE
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products/Services/Solutions offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Service launches
      • 16.1.14.3.2 Deals
  • 16.1.15 MEDIAN TECHNOLOGIES
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products/Services/Solutions offered
  • 16.1.16 LANTERN PHARMA INC.
    • 16.1.16.1 Business overview
    • 16.1.16.2 Products/Services/Solutions offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Deals
  • 16.1.17 CITELINE, A NORSTELLA COMPANY
    • 16.1.17.1 Business overview
    • 16.1.17.2 Products/Services/Solutions offered
    • 16.1.17.3 Recent developments
      • 16.1.17.3.1 Solution launches
      • 16.1.17.3.2 Deals
  • 16.1.18 TRINETX, LLC
    • 16.1.18.1 Business overview
    • 16.1.18.2 Products/Services/Solutions offered
    • 16.1.18.3 Recent developments
      • 16.1.18.3.1 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 REVIVEMED INC.
  • 16.2.2 EURETOS
  • 16.2.3 VERISIM LIFE
  • 16.2.4 TRIOMICS
  • 16.2.5 ARDIGEN
  • 16.2.6 QUANTHEALTH LTD.
  • 16.2.7 DEEP GENOMICS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS